Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Should l Buy BSX?
Source: NASDAQ.COM
- New Drug Approval: Sanofi's Teizeild receives EU approval as the first disease-modifying therapy for Stage 2 Type 1 Diabetes, demonstrating a median delay of 48.4 months to Stage 3 T1D, significantly enhancing patient quality of life and strengthening the company's competitive position in diabetes treatment.
- FDA Approval: Fortress Biotech's ZYCUBO gains FDA approval as the first treatment for Menkes Disease, showing nearly an 80% reduction in mortality risk when used early, laying a solid foundation for future market expansion and revenue growth.
- Acquisition Deal: Boston Scientific's $14.5 billion acquisition of Penumbra reflects its strategic expansion in interventional therapies, expected to enhance its leadership in vascular treatments and drive future revenue growth.
- Clinical Trial Progress: Creative Medical's CELZ-201 shows significant improvement in 79% of patients in the ADAPT trial for chronic lower back pain, indicating the therapy's clinical potential and likely attracting further investment and partnership opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 64.230
Low
94.00
Averages
108.14
High
132.00
Current: 64.230
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Class Action Reminder for Investors
- Lawsuit Background: Boston Scientific's disappointing fourth quarter and full year 2025 results, particularly in U.S. Electrophysiology sales, led to a 17.6% stock price drop to $75.50 on February 4, 2026, causing significant investor losses.
- Investor Reminder: Investors must file a lead plaintiff motion by May 4, 2026, to recover losses incurred from purchasing Boston Scientific securities between July 23, 2025, and February 3, 2026, highlighting concerns over the company's future prospects.
- False Statements Allegations: The lawsuit alleges that Boston Scientific made misleading statements during the class period, failing to disclose that its Electrophysiology segment's growth was unsustainable and that new competitors were eroding market share, thus limiting growth potential.
- Market Reaction: The company's failure to accurately disclose the true state of its Electrophysiology division has severely undermined investor confidence in its future, reflecting a significant erosion of trust in the management's statements.
See More
Wall Street Earnings Season Faces Major Test
- Earnings Season Significance: Wall Street is set for a packed earnings season featuring key companies like Capital One and Boeing, with investors eager to glean insights into the economic impact of the Iran war from these reports.
- Capital One Performance Focus: Capital One is scheduled to report earnings on Tuesday, with market attention on its consumer health metrics and the progress of its acquisitions of Discover and Brex, particularly amid rising economic uncertainties.
- Boeing Earnings Outlook: Boeing is expected to release its earnings report on Wednesday, with market focus on order volumes in both its commercial and defense sectors, as well as free cash flow performance, especially after previous unexpected losses.
- GE Vernova Order Growth: GE Vernova will report alongside Boeing, with first-quarter new orders anticipated to reach $14.4 billion, reflecting a 65% year-over-year increase, indicating strong market performance amid rising electricity demand.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, targeting investors who purchased its securities between July 23, 2025, and February 3, 2026, highlighting significant deficiencies in the company's financial transparency.
- False Statements Allegations: The complaint alleges that Boston Scientific's projected growth rate in its U.S. electrophysiology segment was unsustainable, and that management's optimistic forecasts lacked a reasonable basis, potentially leading to severe investor confidence erosion regarding the company's future.
- Market Impact: As the company grapples with adverse trends such as declining procedure volumes, increased competitive pressures, and regulatory hurdles, investors may face greater financial losses in the future, further impacting stock price performance.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, to share in any potential recovery from the lawsuit, underscoring the importance of legal action in protecting investor rights.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, targeting investors who purchased its securities between July 23, 2025, and February 3, 2026, highlighting significant transparency issues during this period.
- False Statement Allegations: The complaint alleges that executives made materially false and misleading statements regarding financial forecasts, particularly lacking a reasonable basis for the growth projections of the U.S. electrophysiology segment, which could severely undermine investor confidence in the company's future.
- Market Impact: The company is reportedly experiencing adverse trends such as declining procedure volumes and increasing competitive pressures, which may lead to greater financial losses for investors and further negatively impact stock performance.
- Investor Actions: Affected investors are encouraged to apply to become lead plaintiffs by May 4, 2026, to seek compensation in the lawsuit, indicating the potential reputational and market trust implications of this legal action.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding firms that merely act as intermediaries, to ensure they receive the best legal support and potential compensation in the class action.
See More
Cash-Rich Companies: Strong Flow but Investment Risks
- SunOpta's Declining Performance: SunOpta (NASDAQ:STKL) has seen a 1.6% annual decline in sales over the past three years, and despite a free cash flow margin of 4.8%, its revenue base of $792.4 million puts it at a disadvantage, indicating a lack of loyal customers for its products.
- ProFrac's Financial Strain: ProFrac (NASDAQ:ACDC) has a poor free cash flow margin of just 1%, with a gross margin of 32.8% that is below its competitors, limiting its ability to invest in exploration and production, while its EBITDA margin has decreased by 1.6 percentage points over the last five years.
- Boston Scientific's Growth Potential: Boston Scientific (NYSE:BSX) has achieved an average organic revenue growth rate of 16.6% over the past two years, with annual earnings per share growth of 26%, and a free cash flow margin that increased by 7 percentage points over five years, showcasing its strong profitability and investment potential.
- Rising Market Attention: While SunOpta and ProFrac face challenges, Boston Scientific's stock price of $64.08, with a P/E ratio of 18.7, indicates increasing attractiveness in the market, potentially making it a focal point for investors.
See More
Boston Scientific Class Action Reminder for Investors
- Lawsuit Background: Boston Scientific's disappointing fourth quarter and full year 2025 results, particularly in U.S. Electrophysiology sales, led to a 17.6% stock price drop to $75.50 on February 4, 2026, causing significant investor losses.
- Investor Reminder: Investors must file a lead plaintiff motion by May 4, 2026, to recover losses incurred from purchasing Boston Scientific securities between July 23, 2025, and February 3, 2026, highlighting concerns over the company's future prospects.
- False Statements Allegations: The lawsuit alleges that Boston Scientific made misleading statements during the class period, failing to disclose that its Electrophysiology segment's growth was unsustainable and that new competitors were eroding market share, thus limiting growth potential.
- Market Reaction: The company's failure to accurately disclose the true state of its Electrophysiology division has severely undermined investor confidence in its future, reflecting a significant erosion of trust in the management's statements.
See More
Wall Street Earnings Season Faces Major Test
- Earnings Season Significance: Wall Street is set for a packed earnings season featuring key companies like Capital One and Boeing, with investors eager to glean insights into the economic impact of the Iran war from these reports.
- Capital One Performance Focus: Capital One is scheduled to report earnings on Tuesday, with market attention on its consumer health metrics and the progress of its acquisitions of Discover and Brex, particularly amid rising economic uncertainties.
- Boeing Earnings Outlook: Boeing is expected to release its earnings report on Wednesday, with market focus on order volumes in both its commercial and defense sectors, as well as free cash flow performance, especially after previous unexpected losses.
- GE Vernova Order Growth: GE Vernova will report alongside Boeing, with first-quarter new orders anticipated to reach $14.4 billion, reflecting a 65% year-over-year increase, indicating strong market performance amid rising electricity demand.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, targeting investors who purchased its securities between July 23, 2025, and February 3, 2026, highlighting significant deficiencies in the company's financial transparency.
- False Statements Allegations: The complaint alleges that Boston Scientific's projected growth rate in its U.S. electrophysiology segment was unsustainable, and that management's optimistic forecasts lacked a reasonable basis, potentially leading to severe investor confidence erosion regarding the company's future.
- Market Impact: As the company grapples with adverse trends such as declining procedure volumes, increased competitive pressures, and regulatory hurdles, investors may face greater financial losses in the future, further impacting stock price performance.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, to share in any potential recovery from the lawsuit, underscoring the importance of legal action in protecting investor rights.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, targeting investors who purchased its securities between July 23, 2025, and February 3, 2026, highlighting significant transparency issues during this period.
- False Statement Allegations: The complaint alleges that executives made materially false and misleading statements regarding financial forecasts, particularly lacking a reasonable basis for the growth projections of the U.S. electrophysiology segment, which could severely undermine investor confidence in the company's future.
- Market Impact: The company is reportedly experiencing adverse trends such as declining procedure volumes and increasing competitive pressures, which may lead to greater financial losses for investors and further negatively impact stock performance.
- Investor Actions: Affected investors are encouraged to apply to become lead plaintiffs by May 4, 2026, to seek compensation in the lawsuit, indicating the potential reputational and market trust implications of this legal action.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding firms that merely act as intermediaries, to ensure they receive the best legal support and potential compensation in the class action.
See More
Cash-Rich Companies: Strong Flow but Investment Risks
- SunOpta's Declining Performance: SunOpta (NASDAQ:STKL) has seen a 1.6% annual decline in sales over the past three years, and despite a free cash flow margin of 4.8%, its revenue base of $792.4 million puts it at a disadvantage, indicating a lack of loyal customers for its products.
- ProFrac's Financial Strain: ProFrac (NASDAQ:ACDC) has a poor free cash flow margin of just 1%, with a gross margin of 32.8% that is below its competitors, limiting its ability to invest in exploration and production, while its EBITDA margin has decreased by 1.6 percentage points over the last five years.
- Boston Scientific's Growth Potential: Boston Scientific (NYSE:BSX) has achieved an average organic revenue growth rate of 16.6% over the past two years, with annual earnings per share growth of 26%, and a free cash flow margin that increased by 7 percentage points over five years, showcasing its strong profitability and investment potential.
- Rising Market Attention: While SunOpta and ProFrac face challenges, Boston Scientific's stock price of $64.08, with a P/E ratio of 18.7, indicates increasing attractiveness in the market, potentially making it a focal point for investors.
See More
